In response to COVID-19, GHX is committed to helping ensure that our customers receive access to the data and information needed to help maintain critical supplies to serve patients and protect staff. Click to learn more
Log In

Download a pdf of the presentation.

During this webinar, Lumere experts Samantha Bastow, PharmD, and Grace Fox, PhD, highlight the evidence associated with Sugammadex for reversal of neuromuscular blockade during surgery. Key takeaways include:

  • Sugammadex has been shown to decrease time to recovery and residual neuromuscular blockade compared to neostigmine and glycopyrrolate.
  • The clinical and operational significance of existing evidence should be determined based on institution-specific factors to determine place on formulary.
  • Restrictions should be proactively identified and compliance (restriction criteria and appropriate dosing) should be reviewed and reported at a regular cadence.